Q32 Bio Inc.
Price
Key statistics
- Forward rate
- $0.00
- Yield
- 0.00%
- Payout ratio
- 0.00%
- Frequency
- Unknown
Q32 Bio Inc. is a clinical-stage biotechnology company focused on developing biologic therapies for autoimmune and inflammatory diseases driven by immune system dysfunction. The company’s current programs center on restoring healthy immune balance through targeted modulation of the adaptive and innate immune systems, with a lead emphasis on treatments for alopecia areata and other immune-mediated conditions. Q32 Bio’s pipeline includes bempikibart, an antibody-based candidate designed to regulate immune signaling in dermatology and related autoimmune settings, as well as research efforts in complement-pathway biology for tissue-targeted immune control. The company’s work is positioned within the broader biopharmaceutical sector, where precision immunology and biologics play an important role in addressing chronic diseases with limited treatment options. Based in Waltham, Massachusetts, Q32 Bio continues to operate as a research-focused company advancing specialized therapies from clinical development programs.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Ms. Jodie Pope Morrison
- Employees
- 25
- Headquarters
- Waltham, MA, United States
- Website
- www.q32bio.com